Tigecycline dosage in ckd patient. Also is colistin required to be added to tigecycline?
Reading File
Finding Sources
Finding Sources
Searching PubMed
tigecycline renal impairment dosing
Searching PubMed
tigecycline colistin combination therapy
Reading File
Reading File
Reading File
I now have comprehensive information from multiple authoritative textbooks. Let me compile a thorough answer.
Tigecycline in CKD - Dosage & Need for Colistin Combination
1. Tigecycline Dosage in CKD/Renal Impairment
No dose adjustment is required in chronic kidney disease (CKD) or any degree of renal impairment.
This is one of the most important pharmacokinetic properties that distinguishes tigecycline from most other antibiotics. The reasoning is straightforward:
- Tigecycline is eliminated primarily via biliary/fecal route - this is the dominant pathway
- Renal clearance is only a secondary, minor route
- The drug therefore does not accumulate in renal failure
Standard dosing applies regardless of CKD stage or dialysis status:
| Dose | Regimen |
|---|---|
| Loading dose | 100 mg IV once |
| Maintenance | 50 mg IV q12h |
"Doxycycline and tigecycline, in contrast to other tetracyclines, are eliminated by nonrenal mechanisms and do not accumulate significantly in renal failure, requiring no dosage adjustment." - Katzung's Basic & Clinical Pharmacology, 16th Ed.
"No dose adjustment is needed in patients with renal dysfunction." - Goodman & Gilman's Pharmacological Basis of Therapeutics
"No dosage adjustments are necessary for patients with renal impairment; however, a dose reduction is recommended in severe hepatic dysfunction." - Lippincott Illustrated Reviews: Pharmacology
What DOES require adjustment: Severe hepatic dysfunction (Child-Pugh C) - reduce maintenance dose to 25 mg q12h (keep loading dose at 100 mg).
2. Should Colistin (or Other Agents) Be Added to Tigecycline?
Yes - for most serious/invasive infections, tigecycline should NOT be used as monotherapy. This is an FDA black-box warning issue.
Why combination therapy?
A pooled analysis of 13 clinical trials found increased risk of death and treatment failure with tigecycline monotherapy, leading the FDA to mandate a black-box warning. Tigecycline as a single agent has been repeatedly shown to be inferior in serious infections.
When is tigecycline + colistin used?
This combination is specifically indicated for multidrug-resistant (MDR) gram-negative infections, particularly:
- Carbapenem-resistant Acinetobacter baumannii (CRAB)
- Carbapenem-resistant Klebsiella pneumoniae (CRKP)
- Other extensively drug-resistant (XDR) gram-negatives
From Harrison's Principles of Internal Medicine, 22nd Ed. (2025):
"This drug [tigecycline] has been used in combination with colistin for the treatment of serious infections with multidrug-resistant gram-negative organisms."
From Fishman's Pulmonary Diseases & Disorders:
"Tigecycline monotherapy is not recommended, but this agent can be combined with a carbapenem, colistin, or sulbactam."
2024 IDSA Guidance for CRAB (from Harrison's 22E, citing IDSA 2024):
For carbapenem-resistant A. baumannii, the preferred and alternative regimens are:
| Priority | Regimen |
|---|---|
| Preferred | Sulbactam-durlobactam + carbapenem |
| Alternative | High-dose ampicillin-sulbactam + polymyxin B, minocycline, tigecycline, or cefiderocol |
Tigecycline dosing for CRAB in Harrison's Table 167-1:
200 mg loading dose followed by 100 mg q12h (double the standard dose) - used in combination therapy
Note: Polymyxin B is generally preferred over colistin for bloodstream infections due to more predictable PK.
Key practical point on colistin in CKD:
An important caveat - if you are considering the colistin side of the combination in a CKD patient, colistin (unlike tigecycline) DOES require significant dose adjustment for renal impairment and carries nephrotoxicity risk. This makes it a particularly hazardous choice in CKD patients. Polymyxin B may be preferred as it has less renal toxicity and more predictable pharmacokinetics.
Summary
| Question | Answer |
|---|---|
| Tigecycline dose in CKD | No adjustment needed - standard 100 mg load, then 50 mg q12h |
| Hepatic impairment (severe) | Reduce to 25 mg q12h maintenance |
| Monotherapy recommended? | No - FDA black-box warning for increased mortality |
| Colistin needed? | For MDR/XDR gram-negatives (CRAB, CRKP) - yes, combination is standard |
| Alternative partners | Carbapenem, sulbactam, polymyxin B, minocycline, cefiderocol |
| Colistin in CKD | Use with caution - requires dose adjustment and carries nephrotoxicity risk; polymyxin B preferred |
- Harrison's Principles of Internal Medicine, 22E (2025)
- Katzung's Basic and Clinical Pharmacology, 16th Ed.
- Goodman & Gilman's Pharmacological Basis of Therapeutics
- Lippincott Illustrated Reviews: Pharmacology
- Fishman's Pulmonary Diseases & Disorders
Colistin dose and renal adjusted dose
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching the Web
colistin CMS renal dose adjustment CrCl table 2024
Excellent - I now have comprehensive, detailed information from both textbooks and current dosing guidelines. Here is the complete answer.
Colistin - Standard Dose & Renal-Adjusted Dosing
Important note on terminology: Colistin is administered parenterally as colistimethate sodium (CMS), the inactive prodrug. Doses are expressed in either million international units (MIU) or mg of colistin base activity (CBA). These are NOT interchangeable - always check which unit is being used. Confusion here is a real source of dosing errors.
Conversion: 1 MIU CMS ≈ 30 mg CBA ≈ 80 mg CMS
Standard Dosing (Normal Renal Function)
| Component | Dose |
|---|---|
| Loading dose | 300 mg CBA (= 9 MIU) IV × 1 - unaffected by renal function |
| Maintenance | 150-180 mg CBA (= ~4.5-5.4 MIU) q12h |
| First maintenance dose | Give 12-24h after the loading dose |
- The loading dose is always given regardless of renal function - this ensures rapid attainment of therapeutic levels
- Goldman-Cecil Medicine: "A loading dose of 300 mg should be administered, followed by maintenance dosing of 150 to 180 mg every 12 hours, with subsequent dose adjustments made according to renal function."
- Washington Manual: 300 mg IV × 1, then 180 mg IV q12h
Renal-Adjusted Maintenance Dosing (CBA in mg/day)
Based on the Garonzik PK model and NHS/UNMC guidelines:
| CrCl (mL/min) | Dose | Frequency |
|---|---|---|
| >90 | 180 mg | q12h |
| 70-90 | 150-170 mg | q12h |
| 50-70 | 245-275 mg | Once daily (divided) |
| 30-49 | 195-220 mg | Once daily |
| 10-29 | 160-175 mg | Once daily |
| <10 (no dialysis) | 130-145 mg | Once daily |
In MIU equivalents (NHS High-Dose Guideline):
| CrCl (mL/min) | Dose (MIU) | Frequency |
|---|---|---|
| >50 | 3 MIU | q8h |
| 30-49 | 3 MIU | q12h |
| 10-29 | 2.5 MIU | q12h |
| <10 | 1.75 MIU | q12h |
| Hemodialysis (HD) | 1.5 MIU | q12h; 2nd dose given post-HD on dialysis days |
| CAPD | 2.5 MIU | q12h |
| CVVHD/CRRT | Same as CrCl >50 | q12h |
Why Renal Adjustment is Mandatory
The pharmacokinetics of CMS are complex and unique:
- CMS (prodrug) is eliminated almost entirely by the kidneys
- Active colistin generated from CMS has mainly non-renal clearance
- In renal failure, CMS accumulates - but less is converted to active colistin because the prodrug is cleared renally before conversion
- Net result: renal impairment paradoxically lowers active colistin levels AND increases nephrotoxicity risk
- There is significant inter-patient variability - expert consultation and TDM (trough levels) are strongly recommended
Goodman & Gilman's: "There is significant interpatient variability in active colistin sulfate levels due to the competing effects of mostly renal elimination of the CMS parent drug, conversion of CMS to active colistin, and mostly nonrenal elimination of active colistin."
Colistin vs. Polymyxin B in Renal Impairment
| Feature | Colistin (CMS) | Polymyxin B |
|---|---|---|
| Prodrug? | Yes (CMS → colistin) | No - active drug directly |
| Renal elimination | CMS: mainly renal | Mainly non-renal |
| Dose adjustment in CKD? | Yes - mandatory | No (preferred in CKD/renal failure for this reason) |
| Preferred for UTI? | Yes (achieves high urine levels) | No |
| Preferred for bloodstream/MDR? | Less preferred | More preferred |
Goodman & Gilman's: "Polymyxin B is preferred for treatment of most systemic infections, while CMS is recommended for treatment of infections originating in the urinary tract."
Key Safety Points
- Nephrotoxicity in ~30% of patients - dose-dependent
- Monitor serum creatinine daily for the first week
- Avoid concomitant aminoglycosides, NSAIDs, other nephrotoxins
- Neurotoxicity (~10%) - paresthesias, slurred speech, peripheral numbness, neuromuscular blockade at high doses - apnea possible
- Overdose in renal failure can cause neuromuscular blockade and apnea
- TDM (plasma trough levels) recommended in renal impairment
Washington Manual: "The dosage should be carefully reduced in patients with renal insufficiency because overdosage can result in neuromuscular blockade and apnea."
Bottom line: Always use a loading dose (unaffected by renal function), then adjust maintenance dose strictly by CrCl. In severe CKD or dialysis patients, consider whether polymyxin B (no renal adjustment needed) is a better choice for systemic infections. Expert/pharmacy consultation is recommended given the complexity of CMS dosing.
- Goldman-Cecil Medicine, International Ed.
- Goodman & Gilman's Pharmacological Basis of Therapeutics
- Washington Manual of Medical Therapeutics
- NHS Tayside High-Dose Colistin Guideline; UNMC Colistin Dosing Guidelines
This is a shared conversation. Sign in to Orris to start your own chat.